Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,263 across all filing types
Latest filing 2023-06-01 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) notifying them under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. It informs about the receipt of permission (Form CT20) from a government regulatory body (Central Drugs Standard Control Organisation) for import and sale of a pharmaceutical product. The content is an update on regulatory approval and does not contain financial data, earnings, or detailed report information. It is an announcement of a regulatory event relevant to the company’s operations and compliance. The document length is short (1723 characters), and it is clearly an intimation or announcement rather than a full report or detailed filing. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-06-01 English
Copy of Newspaper Publication
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for omitted pictures and no substantive text content. There is no indication of any report, announcement, or filing type. The document length is very short (164 characters) and contains no financial data, regulatory references, or report titles. Given the lack of content, the document cannot be classified as a report or announcement. It defaults to Regulatory Filings (RNS) as a fallback category for miscellaneous or non-classifiable filings.
2023-06-01 English
Please find the enclosed document of the Company with reference to the captioned subject for your reference.
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. It informs about the receipt of permission (Form CT20) from a government regulatory body (Central Drugs Standard Control Organisation) for import and sale of a pharmaceutical product. The content is an official announcement of a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is short (1723 characters) and it serves as an intimation or announcement to the stock exchanges rather than a detailed report. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-06-01 English
Please find the enclosed document of the Company in relation to the captioned subject.
Regulatory Filings
2023-06-01 English
Dividend
Notice of Dividend Amount Classification · 100% confidence The document is a letter addressed to stock exchanges regarding the recommendation of a dividend for the financial year 2022-23. It states that the Board of Directors has recommended a dividend amount per equity share, subject to shareholder approval at the upcoming AGM. The document does not contain actual financial statements or detailed financial data, but rather an announcement about the dividend recommendation. This fits the definition of a Notice of Dividend Amount (DIV), which includes announcements of dividend amounts and payment details.
2023-05-30 English
We wish to inform that at the Meeting of the Board of Directors of the Company held on May 30, 2023, the Board has recommended Dividend of Rs. 16/- per equity share of Rs. 2/- each, subject ....
Notice of Dividend Amount Classification · 100% confidence The document is a letter addressed to stock exchanges regarding the recommendation of a dividend for the financial year 2022-23. It mentions the Board of Directors' decision to recommend a dividend subject to shareholder approval at the upcoming AGM. The document does not contain actual financial statements or detailed financial data but is an announcement related to dividend payment. Therefore, it fits the category of a Notice of Dividend Amount (DIV). The document length is short and focused solely on dividend recommendation, confirming it is not a full report or other filing type.
2023-05-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.